.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Novartis
Healthtrust
QuintilesIMS
Boehringer Ingelheim
Cantor Fitzgerald
Baxter
Mallinckrodt
Cerilliant
McKinsey

Generated: November 21, 2017

DrugPatentWatch Database Preview

XTORO Drug Profile

« Back to Dashboard

What is the patent landscape for Xtoro, and when can generic versions of Xtoro launch?

Xtoro is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are five patents protecting this drug.

This drug has seventy-eight patent family members in thirty-five countries.

The generic ingredient in XTORO is finafloxacin. Additional details are available on the finafloxacin profile page.

Summary for XTORO

US Patents:5
Applicants:1
NDAs:1
Bulk Api Vendors: 9
Drug Prices:see details
DailyMed Link:XTORO at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
XTORO
finafloxacin
SUSPENSION/DROPS;OTIC206307-001Dec 17, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Novartis Pharms Corp
XTORO
finafloxacin
SUSPENSION/DROPS;OTIC206307-001Dec 17, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
XTORO
finafloxacin
SUSPENSION/DROPS;OTIC206307-001Dec 17, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Novartis Pharms Corp
XTORO
finafloxacin
SUSPENSION/DROPS;OTIC206307-001Dec 17, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Novartis Pharms Corp
XTORO
finafloxacin
SUSPENSION/DROPS;OTIC206307-001Dec 17, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Novartis Pharms Corp
XTORO
finafloxacin
SUSPENSION/DROPS;OTIC206307-001Dec 17, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
XTORO
finafloxacin
SUSPENSION/DROPS;OTIC206307-001Dec 17, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: XTORO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp
XTORO
finafloxacin
SUSPENSION/DROPS;OTIC206307-001Dec 17, 2014► Subscribe► Subscribe
Novartis Pharms Corp
XTORO
finafloxacin
SUSPENSION/DROPS;OTIC206307-001Dec 17, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: XTORO

Country Document Number Estimated Expiration
Spain2175519► Subscribe
Canada2765852► Subscribe
Slovakia79599► Subscribe
Philippines12015501230► Subscribe
Czech Republic297363► Subscribe
Canada2888641► Subscribe
China102470139► Subscribe
China1245428► Subscribe
European Patent Office2928475► Subscribe
Brazil9714032► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Johnson and Johnson
McKinsey
Argus Health
Moodys
Baxter
McKesson
Fuji
Deloitte
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot